Treatment strategies for unruptured intracranial aneurysms in the Chinese population: China Treatment Trial for Unruptured Intracranial Aneurysm (ChTUIA)
Open Access
- 3 April 2025
- journal article
- research article
- Published by Springer Nature in Chinese Neurosurgical Journal
- Vol. 11 (1) , 1-8
Abstract
Background: Intracranial aneurysm is a leading cause of subarachnoid hemorrhage and affects approximately 7% of the Chinese population, posing a significant public health concern. Due to the lack of a national cohort of unruptured intracranial aneurysms (UIAs) in China, optimal surgical management for UIAs remain insufficiently explored. Methods: The China Treatment Trial for Unruptured Intracranial Aneurysm (ChTUIA) is a national, prospective, observational, multi-center registry study designed to identify optimal surgical management for UIAs in the Chinese population. Eligible patients were recruited from 83 regional neurological centers in China between December 2021 and December 2022. All patients will be followed up routinely for at least two years. Results: A total of 25,438 patients with UIAs have been enrolled in the study, of whom 9794 (38.5%) were male, with a median age of 59 years (interquartile range: 52–67 years). The mean follow-up period was 4.28 years (interquartile range: 2.86–6.37 years). Among the patients, 6,712 (26.4%) patients underwent microsurgical clipping, and 18,726 (73.6%) patients underwent endovascular treatment, including 3,017 (16.1%) receiving coil alone or balloon-assisted coiling, 11,431 (61.1%) underwent stent-assisted coiling, and 4,278 (22.8%) treated with flow diverters. Comprehensive data collection encompassed 874,890 demographic and clinical records, 42,109 radiological records, 13,528 hemodynamic records, and 12,727 biological records, with a lost-to-follow-up rate of 5.4% and a data-missing rate of 8.3%. Conclusions: The ChTUIA study represents the first national prospective investigation into surgical management protocols and treatment trends toward UIAs in the Chinese population. This study will provide critical evidence to guide the clinical management of UIA patients. Trial registration: NCT05844163 (https://clinicaltrials.gov/study/NCT05844163 ).Keywords
This publication has 12 references indexed in Scilit:
- Surveillance of Unruptured Intracranial AneurysmsNeurology, 2022
- Treatment and diagnosis of cerebral aneurysms in the post-International Subarachnoid Aneurysm Trial (ISAT) era: trends and outcomesJournal of NeuroInterventional Surgery, 2020
- Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet, 2019
- A survey of intracranial aneurysm treatment practices among United States physiciansJournal of NeuroInterventional Surgery, 2017
- The Burden of Hypertension and Associated Risk for Cardiovascular Mortality in ChinaJAMA Internal Medicine, 2016
- Unruptured intracranial aneurysms: epidemiology, natural history, management options, and familial screeningThe Lancet Neurology, 2014
- Cost-effectiveness of preventive treatment of intracranial aneurysmsNeurology, 2009
- Treatment of Unruptured Intracranial Aneurysms: Decision and Cost-effectiveness AnalysisRadiology, 2007
- Preoperative Prediction of Long-term Outcome in Poor-grade Aneurysmal Subarachnoid HemorrhageNeurosurgery, 2006
- Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatmentThe Lancet, 2003